Microbiome Competitive Landscape 2022 | 130+ Companies and 200+ Drugs

DelveInsight's Microbiome Competitive landscape 2022," report provides comprehensive insights about 130+ companies and 200+ drugs in Microbiome Competitive landscape. It covers the Microbiome therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Microbiome Competitive Report

• DelveInsight's Microbiome report depicts a robust space with 130+ active players working to develop 200+ pipeline therapies for Microbiome treatment.

• The leading Microbiome Companies includes Evelo Biosciences, Vedanta Biosciences, MatriSys Biosystem, 4D Pharma, AOBiome, Caelus Health, DA Volterra, Debiopharm, Enterome Bioscience, Rebiotix, Finch Therapeutics Group, Igen Biotech Group, ImmuneBiotech, Precigen Inc, Immuron, Kaleido Biosciences, YSOPIA Bioscience, MaaT Pharma, Microbiome Therapeutics, MyBiotics, Naked Biome, Nubiyota, OxThera, Pylum Biosciences, Ritter Pharmaceuticals, Seres Therapeutics, Symberix, Symbiotix Biotherapies, Xycrobe Therapeutics, Boehringer Ingelheim, BSN Medical GmbH, GlaxoSmithKline, Pfizer, Summit Therapeutics, Institut Pasteur, MetaboGen AB, Johnson & Johnson, Access Business Group, Integrative Skin Science and Research, Verdure Sciences, Seraphic Group Inc, Viome, Sytheon Ltd., Mead Johnson Nutrition, VastBiome, Lei Li, FemTec Health Inc., General Mills, Biotax Labs LTD, HyGIeaCare, Inc., AceTech, Eisai Inc., RenovoDerm, Northwell Health, Napo Pharmaceuticals, Inc., Origimm Biotechnology GmbH, Freya Biosciences ApS, Igenomix, Ganeden Biotech, Inc., BioGaia AB, Ardigen, YUN NV, Persephone Biosciences, Biofortis, Merieux NutriSciences, Lonza Inc., Merck Sharp & Dohme LLC, Evolve BioSystems, Paratek Pharmaceuticals, Winclove Bio Industries BV, Mundipharma Manufacturing Pte Ltd., Bio-Strath AG, Clinical Nutrition Research Center, Illinois Institute of Technology, Igy Nutrition, Pathnostics, Thorne Research Inc., Danone Asia Pacific Holdings Pte, Ltd., NHS Tayside, Varian Medical Systems, Senda Biosciences, Rho Federal Systems Division, Inc., Nutricia, Inc., Ortho Dermatologics, Nestlé, and others

• Promising Microbiome Therapies includes VE-202, MSB-01, Blautix, B244, MRx 518, Thetanix, ABI-M201, ABI-M301, AZT-04, CP 001, DAV 132, Debio 1453, Debio 1454, Debio 1454M, EB-8018, EDP 1503, RBX 2660, MaaT 013, MaaT 033, RBX 7455, FIN-525, FIN-524, Antibody-toxin conjugates, CP101, FIN-211, IMM-529 , IMM-124E, AG 019, AG017, KB 195, KB174, KB 109, Yso1, Yso 2, Yso3, Yso4, Yso5, MaaT 03X, MSB 3163, MSB 5710, MSB 2040, MSB 2179, MSB 6005, MSB 4249, SER-109, SER-155, SER 287, SER 301, and others.

• The Microbiome Competitive Landscape Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends. The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.

To explore more information on the latest breakthroughs in the Microbiome Competitive Landscape of the report, click here Microbiome Competitive Outlook @ https://www.delveinsight.com/sample-request/microbiome-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Microbiome Competitive Overview
Microbiome refers to collection of microbes and their interaction with the human body. Microbiome plays an important role in human physiology and disease. The microbes and their interaction with the human body show the various aspects of human biology. Human body possess a number of different species particularly bacteria and fungi which help in digesting food, preventing infections and performing numerous life-supporting tasks. Microbes can also be harmful to their human hosts.

Latest Developmental Activities of the Microbiome Competitive Landscape

• In July 2022, Tate & Lyle, a leading global provider of food and beverage ingredients and solutions, is delighted to announce that it is extending its partnership with APC Microbiome Ireland, a Science Foundation Ireland (SFI) Research Centre, through a new two-year research project to increase understanding of how dietary fibres can impact the functioning of the gut microbiome.

• In June 2022, Microbiome DX company Genetic Analysis AS ("GA") and Servatus Biopharmaceuticals Ltd ("Servatus"), have entered a Strategic Collaboration Agreement to combine their respective expertise to further advance the microbiome diagnostics and therapeutics markets. The collaboration will bring together Servatus' world class knowledge of biotherapeutics and GA's microbiome diagnostic signature analysis to develop new diagnostic markers and treatment options to ultimately improve the lives of patients worldwide.

• In May 2022, Gnubiotics Sciences SA (Gnubiotics), announced a strategic partnership agreement with ADM, a global leader in human and animal nutrition. The strategic partnership is centered on the commercialization of innovative microbiome solutions for companion animal health and wellbeing. This strategic partnership provides ADM with unique access to cutting edge technologies and a pipeline of microbiome-focused innovation from Gnubiotics.

• In January 2022, BiomeBank, which has recently launched its Series-A funding round, has signed a four-year collaborative agreement with Hudson Institute to translate current and future microbiome research into microbial therapies. This includes a recent deal granting BiomeBank access to important research on how the microbiota could treat paediatric IBD, which is unique because the research used culturing and high-resolution microbial analysis of the colon rather than stool samples. The partnership strengthens Hudson Institute's business case for an Australian-first National Centre for Inflammation Research ("NCIR") and will initially focus on the de

• velopment of defined and targeted microbial therapies to treat unmet medical need for patients with Inflammatory Bowel Disease ("IBD").

• In December 2021, Kaleido Biosciences, Inc. announced the extension and expansion of its research collaboration with Janssen Biotech, Inc. ("Janssen"). The collaboration is designed to explore the potential for Microbiome Metabolic Therapies (MMT™) to prevent childhood-onset of atopic, immune and metabolic conditions by promoting healthy function of the gut microbiome.

Find out more about Microbiome Competitive Landscape Report @ https://www.delveinsight.com/sample-request/microbiome-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Microbiome Drug Profiles
AOBiome
AOBiome Therapeutics is a Boston-based life sciences company focused on transforming human health by developing microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. AOBiome is advancing a pipeline of multiple, clinical-stage therapeutic candidates. The company's portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company has selected its lead candidate based upon pre-clinical and clinical results from those trials. The company has recently completed enrollment of 547 patients in a double blind placebo controlled trial for the treatment of adults with pruritus associated with atopic dermatitis in support of its lead program. Other programs, including Phase 3 acne, may be pursued at a later date.

Product Description: B244
AOBiome's B244 is a patented, proprietary, topical formulation incorporating a single live strain of ammonia-oxidizing bacteria (AOB) Nitrosomonas eutropha D23. It metabolizes the ammonia found in sweat, creating both nitrite and nitric oxide, with both anti-inflammatory and anti-infective properties. The therapeutic drug was designed to repopulate the skin microbiome with AOBs which are normally found on the body but are stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrate, which is known to have anti-bacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. B244 has been observed to be well-tolerated in clinical studies to date. Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31.

4D Pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx,that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism. 4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has five clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, and Blautix® in irritable bowel syndrome (IBS) which has completed a successful Phase II trial. A Phase I study of MRx0005 and MRx0029 in patients with Parkinson's disease is expected to commence in 2022. Additional preclinical-stage programs include candidates for CNS disease, immune-inflammatory conditions and cancer.

Blautix
Blautix is an orally administered drug under development by 4D Pharma. The Drug is in the Phase II stage of development for the treatment of Irritable bowel disease (IBD). Blautix is a single-strain human gut commensal bacterium with a distinctive metabolism which may allow the treatment of IBS. Inside the gut, Blautix consumes gases which are known to cause bloating, abdominal pain, and changes in bowel frequency. The company completed a successful Phase Ib clinical study of Blautix in IBS patients and according to the company, the results were encouraging and provided a solid basis for progressing Blautix into larger clinical studies and further evaluation as a potential treatment for IBS.

MatriSys Biosystem
MatriSys Bioscience is leading the discovery and clinical development of a novel class of biopharmaceuticals to transform the treatment of inflammatory skin diseases. Our groundbreaking technology platform identifies beneficial bacteria derived from healthy human skin to treat the millions of children and adults suffering from difficult to treat chronic skin diseases. With the lead clinical program in patients with Atopic Dermatitis, we are also rapidly advancing therapeutics for Acne and Rosacea.

MSB-01
MSB-01, an anhydrous topical formulation of Staphylococcus hominis strain A9 (Sh-A9) is a topical, highly selective antimicrobial live bio-therapeutic product that replaces the good bacteria that are deficient on the skin on Atopic Dermatitis (AD) patients. It is a commercially viable room-temperature stable topical formulation of freeze-dried S. hominis Strain A9 bacteria for application to the lesional skin of AD patients. AD is associated with the imbalance of skin microbes and a high susceptibility to infection by Staphylococcus Aureus (S. aureus). Staphylococcus hominis strain A9 (S. hominis Sh-A9) present in MSB-01 is selective and potent against the "Bad Bug" S. aureus. Unlike other antibiotics, S. hominis Sh-A9 does not affect other skin microbes and thus leads to the rebalance of the natural skin microbiome. The therapeutic product, MSB-01 is currently in Phase II stage of development for the treatment of Atopic Dermatitis. MSB-01 project is being developed for both therapeutic and cosmetic/skin care endpoints.

Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company's clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer. Vedanta Biosciences controls a foundational portfolio of more than 45 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies, and CGMP-compliant manufacturing of oral Live Biotherapeutic Product (LBP) candidates containing pure, clonally-derived bacterial consortia in powdered form.

VE-202
Vedanta Biosciences, a company of PureTech is developing an innovative class of drugs based on research into the human microbiome. Company's lead product VE202, a microbiome derived therapeutic is in phase I stage of development for the treatment of inflammatory bowel disease (or IBD) and its variants Crohn's Disease (CD) and Ulcerative Colitis (UC). Vedanta believes that VE202 has the potential to be a safer and potentially more efficacious alternative to current IBD drugs such as corticosteroids, anti-tumor necrosis factors, purine analogs, and antibiotics.

Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. Evelo's first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer. Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

EDP1815
EDP1815 is Evelo Biosciences second monoclonal microbial product candidate being developed for the treatment of inflammatory diseases. EDP1815 is currently in phase I for the treatment of Atopic Dermatitis and Psoriasis. Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Psoriasis and Atopic Dermatitis.

Learn more about the Microbiome Drug Development and Microbiome Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/microbiome-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Microbiome Competitive Report

• Coverage- Global

• Microbiome Companies- Evelo Biosciences, Vedanta Biosciences, MatriSys Biosystem, 4D Pharma, AOBiome, Caelus Health, DA Volterra, Debiopharm, Enterome Bioscience, Rebiotix, Finch Therapeutics Group, Igen Biotech Group, ImmuneBiotech, Precigen Inc, Immuron, Kaleido Biosciences, YSOPIA Bioscience, MaaT Pharma, Microbiome Therapeutics, MyBiotics, Naked Biome, Nubiyota, OxThera, Pylum Biosciences, Ritter Pharmaceuticals, Seres Therapeutics, Symberix, Symbiotix Biotherapies, Xycrobe Therapeutics, Boehringer Ingelheim, BSN Medical GmbH, GlaxoSmithKline, Pfizer, Summit Therapeutics, Institut Pasteur, MetaboGen AB, Johnson & Johnson, Access Business Group, Integrative Skin Science and Research, Verdure Sciences, Seraphic Group Inc, Viome, Sytheon Ltd., Mead Johnson Nutrition, VastBiome, Lei Li, FemTec Health Inc., General Mills, Biotax Labs LTD, HyGIeaCare, Inc., AceTech, Eisai Inc., RenovoDerm, Northwell Health, Napo Pharmaceuticals, Inc., Origimm Biotechnology GmbH, Freya Biosciences ApS, Igenomix, Ganeden Biotech, Inc., BioGaia AB, Ardigen, YUN NV, Persephone Biosciences, Biofortis, Merieux NutriSciences, Lonza Inc., Merck Sharp & Dohme LLC, Evolve BioSystems, Paratek Pharmaceuticals, Winclove Bio Industries BV, Mundipharma Manufacturing Pte Ltd., Bio-Strath AG, Clinical Nutrition Research Center, Illinois Institute of Technology, Igy Nutrition, Pathnostics, Thorne Research Inc., Danone Asia Pacific Holdings Pte, Ltd., NHS Tayside, Varian Medical Systems, Senda Biosciences, Rho Federal Systems Division, Inc., Nutricia, Inc., Ortho Dermatologics, Nestlé, and others.

• Microbiome Therapies- VE-202, MSB-01, Blautix, B244, MRx 518, Thetanix, ABI-M201, ABI-M301, AZT-04, CP 001, DAV 132, Debio 1453, Debio 1454, Debio 1454M, EB-8018, EDP 1503, RBX 2660, MaaT 013, MaaT 033, RBX 7455, FIN-525, FIN-524, Antibody-toxin conjugates, CP101, FIN-211, IMM-529 , IMM-124E, AG 019, AG017, KB 195, KB174, KB 109, Yso1, Yso 2, Yso3, Yso4, Yso5, MaaT 03X, MSB 3163, MSB 5710, MSB 2040, MSB 2179, MSB 6005, MSB 4249, SER-109, SER-155, SER 287, SER 301, and others.

Dive deep into rich insights for drugs for Microbiome Unmet Needs, Market Drivers and Barriers, Analyst Views @ https://www.delveinsight.com/sample-request/microbiome-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content

1. Introduction
2. Executive Summary
3. Microbiome: Overview
4. Microbiome Pipeline Therapeutics
5. Microbiome Therapeutic Assessment
6. Microbiome - DelveInsight's Analytical Perspective
7. AOBiome
8. B244 : AOBiome
9. Drug profiles in the detailed report…..
10. 4D Pharma
11. Blautix: 4D Pharma
12. Drug profiles in the detailed report…..
13. MatriSys Biosystem
14. MSB-01: MatriSys Biosystem
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Microbiome Key Companies
18. Microbiome Key Products
19. Microbiome - Unmet Needs
20. Microbiome - Market Drivers and Barriers
21. Microbiome - Future Perspectives and Conclusion
22. Microbiome Analyst Views
23. Microbiome Key Companies
24. Appendix

For further information on the Microbiome Competitive Analysis, reach out @ https://www.delveinsight.com/sample-request/microbiome-competitive-landscape?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.